Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY686017

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyridinesTriazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
In vitro and ex vivo autoradiography of the NK-1 antagonist [3H]-LY686017 in Guinea pig brain
NK-1 receptor antagonists have shown potential for the clinical treatment of chemotherapy-induced nausea and vomiting, depression… Expand
Is this relevant?
2010
2010
Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder
The neurokinin-1 (NK-1) antagonist LY686017 showed activity in preclinical anxiety models. The clinical development of LY686017… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism
Alcohol dependence is a major public health challenge in need of new treatments. As alcoholism evolves, stress systems in the… Expand
Is this relevant?
2008
2008
PKPD Modeling of Brain Receptor Occupancy from Animal to Man for Establishing the Clinical Dose of the NK-1 Antagonist LY686017
: RO simulations with the human PKRO model confirmed the dose of 50 mg QD for POC studies: RO predictions were > 90% as a mean… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE